SR-9009

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H24ClN3O4S
Molecular Weight	437.94
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)N1CCC(CN(CC2=CC=C(S2)[N+]([O-])=O)CC3=CC=C(Cl)C=C3)C1

InChI

InChIKey=MMJJNHOIVCGAAP-UHFFFAOYSA-N

InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3

HIDE SMILES / InChI

Molecular Formula	C20H24ClN3O4S
Molecular Weight	437.94
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22460951

SR9009 is a research drug that was developed in the laboratory of TSRI Professor Thomas Burris as an agonist of nuclear receptors: Rev-ErbA and Rev-ErbAβ). It was demonstrated that REV-ERBs might be used as a novel target to modulate sleep/wake aberrant behavior.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Nuclear receptor subfamily 1 group D member 1 2 Target ID: CHEMBL1961783 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22460951	Agonist 2678		670.0 nM [IC50]
Nuclear receptor subfamily 1 group D member 2 2 Target ID: CHEMBL1961784 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22460951	Agonist 2678		800.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.	2012 Mar 29	22460951
In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011.	2016 Oct 3	27706103

Sample Use Guides

In Vivo Use Guide

in mice: single dose of 100 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

SR9009 dose-dependently (with concentration 0.01-10 nM) increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD) - REV-ERB ligand binding domain (LBD) α or β and a Gal4-responsive luciferase reporter. SR9009 suppresses the expression of BMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:45:11 GMT 2023` Edited by `admin` on `Sat Dec 16 11:45:11 GMT 2023`
Record UNII	X5DCA09N30
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SR-9009

Common Name

English

1-PYRROLIDINECARBOXYLIC ACID, 3-((((4-CHLOROPHENYL)METHYL)((5-NITRO-2-THIENYL)METHYL)AMINO)METHYL)-, ETHYL ESTER

Systematic Name

English

SR 9009 [WHO-DD]

Common Name

English

SR9009

Code

English

SR 9009

Code

English

Code System Code Type Description

FDA UNII

X5DCA09N30